HONG KONG, Nov. 21, 2019 /PRNewswire/ -- Global Cord Blood
Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood
collection, laboratory testing, hematopoietic stem cell processing
and stem cell storage services, today announced that it plans
to release unaudited financial results for the second quarter
and first half of fiscal year 2020 on Tuesday, November 26, 2019, after the market
close.
The Company will host a conference call at 8:00 a.m. ET on
Wednesday, November 27, 2019 to
discuss its financial performance and give a brief overview of the
Company's recent developments, followed by a question and answer
session. Interested parties can access the audio webcast through
the Company's IR website at http://ir.globalcordbloodcorp.com. A
replay of the webcast will be accessible two hours after the
conference call and available for seven days at the same URL as
above. Listeners can also access the call by dialing 1-646-722-4977
or 1-855-824-5644, for US callers, or +852-3027-6500, for
Hong Kong callers, access code:
13679679#.
Please dial in ten minutes prior to the conference call to
ensure proper connection, and be prepared to provide your name and
company name to the operator.
Supplemental financial information referenced in the conference
call and the second quarter and first half of fiscal year 2020
earnings press release will be available at
http://www.globalcordbloodcorp.com, in the section titled "Investor
Center/Press Release", after 4:16 p.m. ET on Tuesday, November 26, 2019, and in the Company's
Report on Form 6-K for the month of November 2019, available
on the Securities and Exchange Commission's website at www.sec.gov.
About Global Cord Blood Corporation
Global Cord Blood Corporation is the first and largest umbilical
cord blood banking operator in China in terms of geographical coverage and
the only cord blood banking operator with
multiple licenses. Under current PRC government
regulations, only one licensed cord blood banking operator is
permitted to operate in each licensed region and no new licenses
will be granted before 2020 in addition to the seven licenses
authorized as of today. Global Cord Blood Corporation provides
cord blood collection, laboratory testing, hematopoietic stem cell
processing and stem cell storage services. For more information,
please visit the Company's website at
http://www.globalcordbloodcorp.com.
For more information, please contact:
Global Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@globalcordbloodcorp.com
ICR, Inc.
William Zima
Tel: (+86) 10-6583-7511
U.S. Tel: (+1) 646-405-5185
Email: william.zima@icrinc.com
View original
content:http://www.prnewswire.com/news-releases/global-cord-blood-corporation-to-report-second-quarter-and-first-half-fiscal-2020-financial-results-300962792.html
SOURCE Global Cord Blood Corporation